Open access
Open access
Powered by Google Translator Translator

Internal Medicine

Interpreting SARS-CoV-2 Test Results.

22 Sep, 2021 | 10:24h | UTC

Interpreting SARS-CoV-2 Test Results – JAMA

 

Long Covid – The illness narratives.

22 Sep, 2021 | 10:19h | UTC

Long Covid – The illness narratives – Social Science & Medicine

 

Commentary on Twitter

https://twitter.com/trishgreenhalgh/status/1439199576158883843

 

AHA Scientific Statement: Weight-loss strategies for prevention and treatment of hypertension.

22 Sep, 2021 | 10:09h | UTC

Weight-Loss Strategies for Prevention and Treatment of Hypertension: A Scientific Statement From the American Heart Association – Hypertension

News release: Weight-loss meds, surgery could fight obesity-related high blood pressure – American Heart Association

 

RCT: Probiotics do not reduce the incidence of ventilator-associated pneumonia in critically ill patients.

22 Sep, 2021 | 10:03h | UTC

Effect of Probiotics on Incident Ventilator-Associated Pneumonia in Critically Ill Patients: A Randomized Clinical Trial – JAMA (free for a limited period)

Commentary: Probiotic Flops for Ventilator-Associated Pneumonia Prevention – MedPage Today (free registration required)

 

Palliative and End-of-Life Care: Prioritizing Compassion Within the ICU and Beyond.

22 Sep, 2021 | 09:57h | UTC

Palliative and End-of-Life Care: Prioritizing Compassion Within the ICU and Beyond – Critical Care Medicine

 

Cluster RCT: Procalcitonin point-of-care testing may reduce antibiotic prescription for patients with suspected lower respiratory tract infection in primary care.

22 Sep, 2021 | 10:01h | UTC

Procalcitonin and lung ultrasonography point-of-care testing to determine antibiotic prescription in patients with lower respiratory tract infection in primary care: pragmatic cluster randomised trial – The BMJ

 

Cluster RCT: Implementing C reactive protein point-of-care testing in nursing homes may reduce antibiotic prescribing for suspected lower respiratory tract infections.

22 Sep, 2021 | 10:02h | UTC

Effect of C reactive protein point-of-care testing on antibiotic prescribing for lower respiratory tract infections in nursing home residents: cluster randomised controlled trial – The BMJ

 

Guidelines Summary: Management of Indwelling Pleural Catheters.

22 Sep, 2021 | 10:00h | UTC

Key Highlights From the American Association for Bronchology and Interventional Pulmonology Evidence-Informed Guidelines and Expert Panel Report for the Management of Indwelling Pleural Catheters – CHEST

 

Residual excessive daytime sleepiness in patients treated for obstructive sleep apnea: guidance for assessment, diagnosis, and management.

22 Sep, 2021 | 09:56h | UTC

Residual excessive daytime sleepiness in patients treated for obstructive sleep apnea: guidance for assessment, diagnosis, and management – Postgraduate Medicine

 

M-A: Safety and efficacy of different prophylactic anticoagulation dosing regimens in critically and non-critically ill patients with COVID-19 – According to this analysis, standard-dose prophylactic anticoagulation should be the standard of care for hospitalized patients with COVID-19 who do not have an indication for therapeutic anticoagulation, irrespective of disease severity.

21 Sep, 2021 | 09:54h | UTC

Safety and efficacy of different prophylactic anticoagulation dosing regimens in critically and non-critically ill patients with COVID-19: A systematic review and meta-analysis of randomized controlled trials – European Heart Journal – Cardiovascular Pharmacotherapy

 

Commentary on Twitter (thread – click for more)

 

COVID will likely shift from pandemic to endemic — but what does that mean?

21 Sep, 2021 | 09:49h | UTC

COVID will likely shift from pandemic to endemic — but what does that mean? – The Conversation

 

Six rules that will define our second pandemic winter

21 Sep, 2021 | 09:47h | UTC

Six Rules That Will Define Our Second Pandemic Winter – The Atlantic

 

KDIGO 2021 clinical practice guideline for the management of glomerular diseases.

21 Sep, 2021 | 09:05h | UTC

KDIGO 2021 clinical practice guideline for the management of glomerular diseases – Kidney Disease: Improving Global Outcomes

Executive summary: KDIGO 2021 Guideline for the Management of Glomerular Diseases – Kidney Disease: Improving Global Outcomes

 

Systematic review: Interventions to Reduce Hospital Length of Stay in High-risk Populations.

21 Sep, 2021 | 08:58h | UTC

Interventions to Reduce Hospital Length of Stay in High-risk Populations: A Systematic Review – JAMA Network Open

 

Review: Transfusion-related acute lung injury in the perioperative patient.

21 Sep, 2021 | 08:56h | UTC

Transfusion-related Acute Lung Injury in the Perioperative Patient – Anesthesiology

 

Podcast: Advance Your Care Planning.

21 Sep, 2021 | 08:51h | UTC

#295 Advance Your Care Planning with Dr. Rebecca Sudore – The Curbsiders

 

CDC Report: Moderna’s vaccine associated with greater effectiveness (93%) against Covid-19 hospitalization compared to Pfizer (88%) and J&J (71%) vaccines.

19 Sep, 2021 | 23:48h | UTC

Comparative Effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) Vaccines in Preventing COVID-19 Hospitalizations Among Adults Without Immunocompromising Conditions — United States, March–August 2021 – CDC Morbidity and Mortality Weekly Report

Commentaries:

Moderna’s vaccine is the most effective, but Pfizer and J&J also protect well, CDC-led study says – CNN

CDC: Moderna COVID vaccine most protective against hospital cases – CIDRAP

CDC data: Moderna vaccine has edge in preventing COVID-19 hospitalizations – UPI

 

Commentary on Twitter

 

Does everybody need a booster shot? – “Why some people might need Covid-19 booster shots — and some might not”.

19 Sep, 2021 | 23:43h | UTC

Does everybody need a booster shot? – Vox

 

An FDA panel says only high-risk Americans and those 65+ should get covid boosters.

19 Sep, 2021 | 23:45h | UTC

An FDA Panel Says Only High-Risk Americans And Those 65+ Should Get COVID Boosters – NPR

See also:

FDA advisory panel recommends booster doses of Covid-19 vaccine only for older and high-risk Americans – STAT

5 reasons why FDA advisers did not recommend Covid-19 booster shots for everyone – CNN

Top doctors say not so fast to Biden’s boosters-for-all plan – Associated Press

Related:

An observational study in Israel suggests additional protection from a 3rd dose of the Pfizer vaccine in individuals 60 years of age or older.

Third shot: UK to offer COVID booster jabs to over 50s.

COVID-19 vaccine efficacy does not support boosters for general population, review concludes.

COVID vaccine effects wane over time but still prevent death and severe illness.

What’s the evidence for COVID-19 booster shots?

WHO appeals for countries to postpone COVID-19 vaccine boosters until 2022 to prioritize vaccinating the most at-risk people around the world who are yet to receive their first dose.

AstraZeneca bosses warn against rush for boosters – “giving the most vulnerable, who may not have built up a full immune response from the first two, a third, top-up dose is “sensible”. But any decision to give a third, booster jab “to large swathes of the population”, to extend their protection from the first two, must be based on clinical data”.

 

COVID vaccine immunity is waning — how much does that matter? – “As debates about booster shots heat up, what’s known about the duration of vaccine-based immunity is still evolving”.

19 Sep, 2021 | 23:40h | UTC

COVID vaccine immunity is waning — how much does that matter? – Nature

 

Side effect patterns in a crossover trial of statin, placebo, and no treatment – This N-of-1 trial, now published in full, suggests the nocebo effect causes most of statins muscle adverse effects.

19 Sep, 2021 | 23:30h | UTC

Side Effect Patterns in a Crossover Trial of Statin, Placebo, and No Treatment – Journal of the American College of Cardiology

See also: #AHA20 – In patients who had discontinued statins because of side effects, a N-of-1 trial of a statin, placebo, or no treatment found that side effects often attributed to statins were the same for those taking a placebo

 

Non-alcoholic fatty liver disease: A patient guideline.

19 Sep, 2021 | 23:35h | UTC

Non-alcoholic fatty liver disease: A patient guideline – JHEP Reports

 

Commentary on Twitter

 

Large cohort study suggests routine replacement (every 96 hours) of peripheral intravenous catheters may reduce the risk of bloodstream infections compared to clinically indicated replacement.

19 Sep, 2021 | 23:34h | UTC

Comparison of Routine Replacement With Clinically Indicated Replacement of Peripheral Intravenous Catheters – JAMA Internal Medicine (free for a limited period)

Related Cochrane Review with different findings: Systematic Review: Clinically‐indicated vs. Routine Replacement of Peripheral Venous Catheters

 

Commentary on Twitter

 

RCT: Rivaroxaban does not have an impact on disease progression and symptoms resolution in high-risk adults with mild COVID-19.

17 Sep, 2021 | 10:19h | UTC

Randomized study of rivaroxaban vs. placebo on disease progression and symptoms resolution in high-risk adults with mild COVID-19 – Clinical Infectious Diseases

 

Management of COVID-19 ICU-survivors in primary care: – a narrative review.

17 Sep, 2021 | 10:13h | UTC

Management of COVID-19 ICU-survivors in primary care: – a narrative review – BMC Family Practice

 

Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.